Glaxo's Arzerra Misses Target in Clinical Trial

GlaxoSmithKline and Genmab said their drug ofatumumab failed to meet its primary endpoint for treating bulky fludarabine-refractory chronic lymphocytic leukemia in a Phase-3 study.



from WSJ.com: US Business http://ift.tt/1qR1s6O

via IFTTT